1. Home
  2. AMPH vs ABUS Comparison

AMPH vs ABUS Comparison

Compare AMPH & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$19.03

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.62

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
ABUS
Founded
1996
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
839.5M
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
AMPH
ABUS
Price
$19.03
$4.62
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$28.38
$5.00
AVG Volume (30 Days)
614.5K
1.5M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
0.14
0.87
Revenue
$719,887,000.00
$14,083,000.00
Revenue This Year
$6.90
N/A
Revenue Next Year
$4.64
$239.71
P/E Ratio
$139.07
$5.07
Revenue Growth
N/A
128.21
52 Week Low
$16.65
$3.04
52 Week High
$31.26
$5.10

Technical Indicators

Market Signals
Indicator
AMPH
ABUS
Relative Strength Index (RSI) 45.67 62.39
Support Level $18.92 $4.15
Resistance Level $19.81 $4.86
Average True Range (ATR) 0.76 0.16
MACD 0.08 0.03
Stochastic Oscillator 41.78 99.15

Price Performance

Historical Comparison
AMPH
ABUS

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: